Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

Completed · Phase 2

Conditions studied: Melanoma, Neoplasm

In brief

The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.

Key facts

Study ID

NCT00062491

Run by

BioNumerik Pharmaceuticals, Inc.

People needed

46

Starts

2002-05-01

Expected to finish

2005-11-01

Last updated by the study team

2020-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• For Information call 210-614-1701 for a site near you — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.